company background image
PCLO logo

PharmaCielo TSXV:PCLO Stock Report

Last Price

CA$0.075

Market Cap

CA$13.6m

7D

-11.8%

1Y

-58.3%

Updated

30 Dec, 2024

Data

Company Financials

PharmaCielo Ltd.

TSXV:PCLO Stock Report

Market Cap: CA$13.6m

PCLO Stock Overview

Together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. More details

PCLO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Does not have a meaningful market cap (CA$14M)

Highly volatile share price over the past 3 months compared to the Canadian market

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

PharmaCielo Ltd. Competitors

Charlotte's Web Holdings

TSX:CWEB

CA$18.9m

Crescita Therapeutics

TSX:CTX

CA$11.5m

4Front Ventures

CNSX:FFNT

CA$27.5m

Red White & Bloom Brands

CNSX:RWB

CA$16.5m

Price History & Performance

Summary of share price highs, lows and changes for PharmaCielo
Historical stock prices
Current Share PriceCA$0.075
52 Week HighCA$0.29
52 Week LowCA$0.065
Beta2.28
1 Month Change-11.76%
3 Month Change-44.44%
1 Year Change-58.33%
3 Year Change-92.35%
5 Year Change-97.79%
Change since IPO-98.72%

Recent News & Updates

Recent updates

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Oct 04
Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Feb 25
Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt

Aug 03
PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt

Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?

Dec 23
Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?

Is PharmaCielo (CVE:PCLO) A Risky Investment?

May 14
Is PharmaCielo (CVE:PCLO) A Risky Investment?

Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?

Feb 16
Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?

Shareholder Returns

PCLOCA PharmaceuticalsCA Market
7D-11.8%-1.1%-0.5%
1Y-58.3%-32.0%14.9%

Return vs Industry: PCLO underperformed the Canadian Pharmaceuticals industry which returned -31.4% over the past year.

Return vs Market: PCLO underperformed the Canadian Market which returned 15.7% over the past year.

Price Volatility

Is PCLO's price volatile compared to industry and market?
PCLO volatility
PCLO Average Weekly Movement20.9%
Pharmaceuticals Industry Average Movement12.1%
Market Average Movement8.1%
10% most volatile stocks in CA Market17.2%
10% least volatile stocks in CA Market2.9%

Stable Share Price: PCLO's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: PCLO's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aMarc Lustigwww.pharmacielo.com

PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. Its products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products.

PharmaCielo Ltd. Fundamentals Summary

How do PharmaCielo's earnings and revenue compare to its market cap?
PCLO fundamental statistics
Market capCA$13.58m
Earnings (TTM)-CA$14.03m
Revenue (TTM)CA$2.60m

4.9x

P/S Ratio

-0.9x

P/E Ratio

Is PCLO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PCLO income statement (TTM)
RevenueCA$2.60m
Cost of RevenueCA$2.57m
Gross ProfitCA$31.08k
Other ExpensesCA$14.06m
Earnings-CA$14.03m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.083
Gross Margin1.20%
Net Profit Margin-540.35%
Debt/Equity Ratio-275.0%

How did PCLO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 06:54
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaCielo Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullStifel Canada
Robert FaganStifel Canada